1. Home
  2. SCYX vs QCLS Comparison

SCYX vs QCLS Comparison

Compare SCYX & QCLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$5.26

Market Cap

51.1M

Sector

Health Care

ML Signal

N/A

Logo Q/C Technologies Inc.

QCLS

Q/C Technologies Inc.

HOLD

Current Price

$2.41

Market Cap

22.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
QCLS
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.1M
22.1M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
SCYX
QCLS
Price
$5.26
$2.41
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
248.0K
145.0K
Earning Date
05-06-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
22.33
EPS
N/A
N/A
Revenue
$257,000.00
$3,929,527.00
Revenue This Year
N/A
N/A
Revenue Next Year
$608.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.71
52 Week Low
$0.57
$2.50
52 Week High
$5.62
$8.17

Technical Indicators

Market Signals
Indicator
SCYX
QCLS
Relative Strength Index (RSI) 59.55 30.26
Support Level $4.65 N/A
Resistance Level $5.56 $3.96
Average True Range (ATR) 0.34 0.18
MACD -0.02 -0.01
Stochastic Oscillator 55.75 13.33

Price Performance

Historical Comparison
SCYX
QCLS

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

Share on Social Networks: